Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jaguar Health Begins IIT for Crofelemer in Short Bowel Syndrome (SBS-IF)
Details : Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug, which is being evaluated for the treatment of short bowel syndrome with intestinal failure.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crofelemer
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jaguar Submits Orphan Drug Designation Application for Crofelemer
Details : Crofelemer is a plant-based drug extracted from red bark sap, being developed for treating moderate-to-severe diarrhea from various infections, including Vibrio cholerae.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Jaguar Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Jaguar Submits Clinical Trial Applications for Crofelemer in Rare Diseases
Details : The company submitted a CTA to the Italian and German health authorities to initiate a phase 2 trial of Mytesi (crofelemer) for the treatment of short bowel syndrome with intestinal failure in adults.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 05, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Jaguar Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jaguar Health Submits Breast Cancer Therapy Diarrhea Impact Study Abstract
Details : Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug administered orally as a delayed release tablet, for prophylaxis of diarrhea in cancer patients.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 10, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Recipient : Lindsey Russell, MD
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2024
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Recipient : Lindsey Russell, MD
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug administered orally as a delayed release tablet, for prophylaxis of diarrhea in cancer patients.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 12, 2023
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crofelemer
Therapeutic Area : Rare Diseases and Disorders
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mytesi (crofelemer) powder for oral solution inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes, which being investigated for the treatment of microvillus inclusion disease.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 08, 2023
Lead Product(s) : Crofelemer
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Crofelemer
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I
Sponsor : Quadri Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Napo grants Quadri Pharma exclusive promotional, commercialization, and distribution rights for a powder formulation of Mytesi (crofelemer), the only oral FDA-approved prescription drug under botanical guidance, for oral solution.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 11, 2023
Lead Product(s) : Crofelemer
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I
Sponsor : Quadri Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Recipient : Jaguar Health
Deal Size : $5.0 million
Deal Type : Agreement
Details : Mytesi, only oral plant-based prescription medicine approved under FDA Botanical Guidance, is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit ...
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 03, 2021
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Recipient : Jaguar Health
Deal Size : $5.0 million
Deal Type : Agreement